PE20081161A1 - COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS - Google Patents

COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Info

Publication number
PE20081161A1
PE20081161A1 PE2007001544A PE2007001544A PE20081161A1 PE 20081161 A1 PE20081161 A1 PE 20081161A1 PE 2007001544 A PE2007001544 A PE 2007001544A PE 2007001544 A PE2007001544 A PE 2007001544A PE 20081161 A1 PE20081161 A1 PE 20081161A1
Authority
PE
Peru
Prior art keywords
tetrahydrocyclopenta
cyane
indol
androgen receptor
receptor modulators
Prior art date
Application number
PE2007001544A
Other languages
English (en)
Spanish (es)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Donald Paul Matthews
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20081161A1 publication Critical patent/PE20081161A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PE2007001544A 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS PE20081161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
PE20081161A1 true PE20081161A1 (es) 2008-08-15

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001544A PE20081161A1 (es) 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Country Status (36)

Country Link
US (1) US7968587B2 (enExample)
EP (1) EP2094658B1 (enExample)
JP (1) JP5399259B2 (enExample)
KR (1) KR101121471B1 (enExample)
CN (1) CN101541749B (enExample)
AR (1) AR063559A1 (enExample)
AT (1) ATE538091T1 (enExample)
AU (1) AU2007324046B2 (enExample)
BR (1) BRPI0719092B8 (enExample)
CA (1) CA2670340C (enExample)
CL (1) CL2007003182A1 (enExample)
CO (1) CO6190513A2 (enExample)
CR (1) CR10802A (enExample)
CY (1) CY1112284T1 (enExample)
DK (1) DK2094658T3 (enExample)
EA (1) EA015627B1 (enExample)
EC (1) ECSP099350A (enExample)
ES (1) ES2376048T3 (enExample)
HR (1) HRP20120032T1 (enExample)
IL (1) IL198410A (enExample)
JO (1) JO2800B1 (enExample)
MA (1) MA31072B1 (enExample)
MX (1) MX2009005251A (enExample)
MY (1) MY154547A (enExample)
NO (1) NO342531B1 (enExample)
NZ (1) NZ576296A (enExample)
PE (1) PE20081161A1 (enExample)
PL (1) PL2094658T3 (enExample)
PT (1) PT2094658E (enExample)
RS (1) RS52191B (enExample)
SI (1) SI2094658T1 (enExample)
TN (1) TN2009000189A1 (enExample)
TW (1) TWI398438B (enExample)
UA (1) UA98777C2 (enExample)
WO (1) WO2008063867A2 (enExample)
ZA (1) ZA200903096B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
PT2568806T (pt) 2010-05-12 2016-08-05 Radius Health Inc Regimes terapêuticos
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
BR112013028895A2 (pt) 2011-05-10 2016-08-09 Bayer Ip Gmbh (tio)carbonilamidinas bicíclicas
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
RS67458B1 (sr) 2014-03-28 2025-12-31 Univ Duke Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
RS63311B1 (sr) 2016-06-22 2022-07-29 Ellipses Pharma Ltd Ar+ metode lečenja raka dojke
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE60032780T2 (de) * 1999-10-14 2007-11-08 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinolin-derivate
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
WO2003097598A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2414604T3 (es) * 2004-03-03 2013-07-22 Eli Lilly And Company Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol
WO2006121466A2 (en) * 2004-11-22 2006-11-16 Smithkline Beecham Corporation Hcv inhibitors
JP2008520741A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス, インコーポレイテッド 翻訳制御によるvegf生成を阻害するための活性因子としてのテトラヒドロカルバゾール
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
MX2007015905A (es) 2005-06-24 2008-03-06 Lilly Co Eli Derivados de tetrahidrocarbazol utiles como moduladores de receptor de androgeno (sarm).
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
BRPI0912394A2 (pt) 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol

Also Published As

Publication number Publication date
CO6190513A2 (es) 2010-08-19
ATE538091T1 (de) 2012-01-15
IL198410A (en) 2013-09-30
JO2800B1 (en) 2014-03-15
TW200827347A (en) 2008-07-01
ZA200903096B (en) 2010-07-28
PL2094658T3 (pl) 2012-05-31
CN101541749A (zh) 2009-09-23
UA98777C2 (en) 2012-06-25
US20100069404A1 (en) 2010-03-18
CY1112284T1 (el) 2015-12-09
BRPI0719092B8 (pt) 2021-05-25
NZ576296A (en) 2011-11-25
DK2094658T3 (da) 2012-02-13
CL2007003182A1 (es) 2008-06-27
MA31072B1 (fr) 2010-01-04
BRPI0719092A2 (pt) 2013-12-03
TWI398438B (zh) 2013-06-11
AU2007324046B2 (en) 2012-04-05
CR10802A (es) 2009-07-13
EA015627B1 (ru) 2011-10-31
US7968587B2 (en) 2011-06-28
TN2009000189A1 (en) 2010-10-18
PT2094658E (pt) 2012-02-22
CA2670340C (en) 2014-05-20
KR20090082229A (ko) 2009-07-29
NO20092103L (no) 2009-05-28
NO342531B1 (no) 2018-06-11
AU2007324046A1 (en) 2008-05-29
ECSP099350A (es) 2009-06-30
SI2094658T1 (sl) 2012-04-30
IL198410A0 (en) 2010-02-17
WO2008063867A3 (en) 2008-07-31
KR101121471B1 (ko) 2012-02-28
EP2094658A2 (en) 2009-09-02
HK1134089A1 (en) 2010-04-16
WO2008063867A2 (en) 2008-05-29
MX2009005251A (es) 2009-08-19
EA200970500A1 (ru) 2009-10-30
RS52191B (sr) 2012-10-31
HRP20120032T1 (hr) 2012-02-29
JP2010510231A (ja) 2010-04-02
CN101541749B (zh) 2013-03-27
CA2670340A1 (en) 2008-05-29
ES2376048T3 (es) 2012-03-08
EP2094658B1 (en) 2011-12-21
AR063559A1 (es) 2009-02-04
BRPI0719092B1 (pt) 2020-08-18
JP5399259B2 (ja) 2014-01-29
MY154547A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
PE20061084A1 (es) Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110152A1 (es) Nuevos derivados de sulfamida sustituida
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20061290A1 (es) Derivados de 1-benzil-indol-2-carboxamida
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20080006A1 (es) Derivados de quinolina como agentes pesticidas
PH12012501456A1 (en) Novel 3-hydroxy -5- arylisothiazole derivative
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
PE20120692A1 (es) Derivados de 5-fluoro-2-oxopirimidinona-1(2h)-carboxamida substituida-n1

Legal Events

Date Code Title Description
FG Grant, registration